2022-11-13T09:43:06-06:00 2021-12-31 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2021-01-01 820656623 THE SILVERSTEIN FOUNDATION FOR PARKINSON'S WITH GBA SILV 9175198108 PO BOX 237137 NEW YORK NY 10023 NATALIE SILVERSTEIN VICE PRES/TREASURER 9175198108 2022-11-11 1 NATALIE SILVERSTEIN 999009999 DAVID M HIGHFILL P01517891 2127589700 2022-11-10 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z JONATHAN SILVERSTEIN PO BOX 237137 NEW YORK NY 10023 2090823 0 X WWW.SILVERSTEINFOUNDATION.ORG X 2017 NY TO RAISE AWARENESS AROUND PARKINSON'S DISEASE ASSOCIATED WITH GBA MUTATIONS; SEE PART III. 3 3 0 3 0 0 67317 36790 0 0 6986 235363 0 0 74303 272153 626701 1481425 0 0 0 0 0 0 0 69221 82657 695922 1564082 -621619 -1291929 4580823 3277845 35601 18915 4545222 3258930 X THE SILVERSTEIN FOUNDATION FOR PARKINSON'S WITH GBA RESEARCH RAISES AWARENESS AROUND PARKINSON'S DISEASE ASSOCIATED WITH GBA MUTATIONS. SEE SCHEDULE O FOR MORE INFORMATION. 0 0 1481425 1481425 SINCE THE LAUNCH OF THE SILVERSTEIN FOUNDATION IN MARCH OF 2017, IT HAS FUNDED OVER 30 GRANTS, RECEIVED DONATIONS FROM OVER 1000 DONORS AND SUPPORTED 7 DIFFERENT THERAPEUTIC APPROACHES, INCLUDING AUTOPHAGY, ANTISENSE OLIGONUCLEOTIDES, GENE THERAPY, ALPHA SYNUCLEIN DEGRADERS, GLUCOCEREBROSIDASE ACTIVATORS, SUBSTRATE REDUCTION THERAPY, AND AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS TO ACCELERATE RESEARCH AND CLINICAL TRIALS TO BRING NEW THERAPEUTIC OPTIONS TO PATIENTS. SEE SCHEDULE O. 1481425 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 3 3 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 NY X JONATHAN T SILVERSTEIN 9175198108 11 RIVERSIDE DRIVE APT PH-W2 NEW YORK NY 10023 X JONATHAN SILVERSTEIN PRESIDENT / SECRETARY 2.00 0.00 X X 0 0 0 NATALIE SILVERSTEIN VICE PRESIDENT / TREASURER 1.00 0.00 X X 0 0 0 GEOFFREY LEVIN BOARD MEMBER 1.00 0.00 X 0 0 0 0 0 0 0 0 0 0 0 36790 36790 2372 2372 2051661 1818670 232991 232991 232991 272153 0 0 235363 1481425 1481425 35974 35974 24200 24200 19693 19693 2790 2790 1564082 1481425 82657 0 X 1896082 3206167 1934711 71678 750030 4580823 3277845 35601 18915 35601 18915 X 4545222 3258930 4545222 3258930 4580823 3277845 -1291929 5637 0 X 0 1 X 0 0 X 6217058 599990 379686 67317 36790 7300841 6217058 599990 379686 67317 36790 7300841 5230133 2070708 14642 61051 49600 6986 2372 134651 7435492 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 277790 5637 5637 272153 0 272153 1564082 0 1564082 0 1564082 PART X, LINE 2: UNCERTAIN TAX POSITIONS THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3). ACCOUNTING STANDARDS PRESCRIBE A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THESE STANDARDS ALSO PROVIDE GUIDANCE ON DE-RECOGNITION OF TAX BENEFITS, CLASSIFICATION ON THE BALANCE SHEET, INTEREST AND PENALTIES, ACCOUNTING IN INTERIM PERIODS, DISCLOSURE, AND TRANSITION. THE FOUNDATION HAS EVALUATED ANY UNCERTAIN TAX POSITIONS AND RELATED INCOME TAX CONTINGENCIES AND DETERMINED UNCERTAIN POSITIONS, IF ANY, ARE NOT MATERIAL TO THE FINANCIAL STATEMENTS. PENALTIES AND INTEREST ASSESSED BY INCOME TAXING AUTHORITIES ARE INCLUDED IN OPERATING EXPENSES, IF INCURRED. TAX RETURNS ARE GENERALLY SUBJECT TO EXAMINATION BY FEDERAL AND STATE TAXING AUTHORITIES FOR THREE YEARS. 1 ACUREX THERAPEUTICS 930 BRITTAN AVENUE SAN CARLOS CA 94070 834462277 1000000 0 N/A RESEARCH HEBREW UNIVERSITY OF JERUSALEM MT SCOPUS CAMPUS JERUSALEM IS 237285905 481425 0 N/A RESEARCH 2 SCHEDULE I, LINE 1 THE SILVERSTEIN FOUNDATION FOR PARKINSON'S WITH GBA MAINTAINS RECORDS TO SUBSTANTIATE THE FUNDING AMOUNT, ELIGIBILITY CRITERIA AND SELECTION CRITERIA USED TO AWARD THE GRANTS. A GRANT CONTRACTING PROCESS SUMMARY PROVIDES DETAILED INSTRUCTIONS AND GUIDANCE FOR THE BOARD AND SCIENTIFIC ADVISORY BOARD (SAB) AS THEY SEEK NEW, CUTTING-EDGE THERAPEUTIC APPROACHES FOR TREATING AND PREVENTING PARKINSON'S DISEASE IN GBA MUTATION CARRIERS. THE SAB, WHICH GUIDES DECISION MAKING IN THE SELECTION PROCESS, IS COMPRISED OF ELEVEN (11) WORLD RENOWNED RESEARCHERS AND DRUG-DEVELOPERS. THEY ARE ABLE TO RAPIDLY COMB THROUGH GBA-RELATED RESEARCH TO ADVANCE OUR GOALS AND DETERMINE WHICH GRANTS SHALL BE AWARDED. THE GRANT CONTRACTING PROCESS OUTLINES THE STEPS THE FOUNDATION TAKES TO SUBSTANTIATE AMOUNTS AND ELIGIBILITY AS FOLLOWS; - PRIMARY INVESTIGATORS (PI'S) ARE ASKED TO SUBMIT A DETAILED RESEARCH PLAN AND COMPLETE MILESTONE AND BUDGET TEMPLATES WHICH ARE REVIEWED BY FOUNDATION STAFF AND SAB MEMBERS. - BUDGET JUSTIFICATION MAY BE REQUIRED. - FOR PRIVATE COMPANIES, HIGH-LEVEL FINANCIAL DOCUMENTS ARE REQUESTED IN ORDER TO PROVIDE CONFIRMATION THAT THE COMPANY HAS FINANCIAL STABILITY THROUGHOUT THE DURATION OF THE GRANT AND BEYOND. - ONCE ALL DOCUMENTS ARE RECEIVED FROM GRANTEE, INTERNAL REVIEW BY ALL SCIENTISTS ENSURES THAT ALL REQUESTS AND GOALS ARE APPROPRIATE. - A CONTRACT TEMPLATE, WHICH INCLUDES PAYMENT SCHEDULE, IS COMPLETED ONCE ALL DOCUMENTS HAVE BEEN VETTED BY INTERNAL STAFF. A PAYMENT SCHEDULE IS DETERMINED AND PAYMENTS ARE BASED UPON MILESTONES AND DELIVERABLES BEING MET. CLEAR GO/NO-GO POINTS FOR THE RESEARCH ARE REQUIRED. - FINAL EXECUTED CONTRACT, INCLUDING BUDGET AND MILESTONES ARE SIGNED BY THE FOUNDATION AND THE GRANTEE, AND ARE KEPT ON FILE. - FOUNDATION PERSONNEL ARE ASSIGNED TO OVERSEE THE PROGRESS OF THE GRANT, BOTH SCIENTIFICALLY AND ADMINISTRATIVELY. PROGRESS UPDATES, CHECK-INS AND REPORTING REQUIREMENTS ARE OUTLINED AND AGREED UPON IN THE CONTRACT AND ARE MONITORED CLOSELY BY PERSONNEL. SCHEDULE I, LINE 2 DESCRIBE THE FOUNDATION'S PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS. THE SILVERSTEIN FOUNDATION FOR PARKINSON'S WITH GBA MAINTAINS A RIGOROUS GRANT MANAGEMENT PROCESS WHICH INVOLVES THE FOLLOWING STEPS: - IDENTIFY POINT OF CONTACT (POC) INTERNALLY AND COMMUNICATE THIS TO GRANTEE. - INFORM GRANTEE THAT THEY WILL BE IN TOUCH WITH POC PROACTIVELY ON: - FIRST MONTH PROGRESS ON RECRUITMENT AND HIRES (CLINICAL GRANT) - MONTHLY PROGRESS ON RECRUITMENT (CLINICAL GRANT) - SCHEDULING A THREE (3) MONTH CALL, MIDPOINT ASSESSMENT CALL AND FINAL ASSESSMENT MEETING/CALL. - SUBMIT MIDPOINT REPORT AND FINAL REPORT TO THE POC PROGRESS AGAINST MILESTONES. PAYMENTS WILL ONLY BE RELEASED IF MILESTONES ARE MET. - GRANTEE WILL NEED TO STAY IN TOUCH TO SHARE UPDATES. - ADJUST PAYMENTS IF MILESTONES ARE DELAYED. IF WORK CANNOT CONTINUE, MODIFICATION OF WORK OR EARLY TERMINATION OF GRANT WOULD BE REQUIRED. - UPON CONFIRMATION THAT PAYMENT CAN BE SENT, INFORM FOUNDATION TREASURER (NATALIE SILVERSTEIN) THREE (3) DAYS IN ADVANCE TO ISSUE PAYMENT. - SHARE GRANTEE NAME, AMOUNT AND BANK INFORMATION. TRACK INFORMATION IN GRANTS TRACKER, PAYMENT TAB. - DURING MIDPOINT AND FINAL REPORT SUBMISSION, ENSURE ALL HIGH-LEVEL DATA, FINDINGS AND RESULTS ARE SHARED IN WRITTEN FORM, EVEN IF GRANTEE PLANS TO SHARE INFORMATION VIA PHONE OR IN PERSON DURING ASSESSMENT MEETING. - FOUNDATION SHALL SAVE ALL REPORTS AND FINAL PRESENTATIONS IN GRANTEE'S FILE AS "REPORTS & RESULTS". FORM 990, PART III, LINE 1, ORGANIZATION'S MISSION CONTINUE FROM PART III: WE AGGRESSIVELY SEEK OUT NEW CUTTING EDGE THERAPEUTIC APPROACHES TO TREATING AND PREVENTING PARKINSON'S IN GBA MUTATION CARRIERS. THROUGH CLINICIANS, SCIENTISTS AND BIOTECH COMPANIES, WE SEEK TO ACCELERATE RESEARCH AND CLINICAL TRIALS IN AN EFFORT TO RAPIDLY BRING NEW THERAPEUTIC OPTIONS TO PATIENTS. FORM 990, PART III, LINE 4A, PROGRAM SERVICES CONTINUE FROM PART III: THE FOUNDATION PREVIOUSLY FUNDED THE FOLLOWING INITIATIVES THAT CONTINUE TO ADVANCE THE MISSION OF THE ORGANIZATION: - PREVAIL THERAPEUTICS, A COMPANY THAT THE FOUNDATION STARTED WITH ASA ABELIOVICH, RAISED $200 MILLION VIA PRIVATE AND PUBLIC FINANCING. PREVAIL RECENTLY ANNOUNCED THAT ENROLLMENT IN THE PR001 PHASE 1/2 PROPEL CLINICAL TRIAL IS PROGRESSING, PATIENT DOSING CONTINUES, AND THE COMPANY IS HOPEFUL THAT IT WILL REMAIN ON TRACK TO REPORT INTERIM DATA ON A SUBSET OF PATIENTS IN THE SECOND HALF OF 2020. - ASPEN NEUROSCIENCE, WHICH WAS SPUN OUT OF SCRIPPS INSTITUTE AND THE LAB OF WORLD-RENOWNED STEM CELL RESEARCHER DR. JEAN LORING, RAISED MORE THAN $70 MILLION TO STUDY AUTOLOGOUS STEM CELL APPROACHES. VANQUA BIO WAS LAUNCHED IN 2019 BASED ON FOUNDATION-FUNDED RESEARCH BEING CONDUCTED IN THE LABORATORY OF DR. DIMITRI KRAINC AT NORTHWESTERN UNIVERSITY. THE COMPANY IS FOCUSED ON DEVELOPING SMALL MOLECULE MODULATORS OF LYSOSOMAL TARGETS THAT HAVE GENETIC LINKAGES TO GBA PD. TOGETHER WITH Q-STATE BIOSCIENCES, THE FOUNDATION LAUNCHED CHAMISHI THERAPEUTICS, A NEW DRUG DISCOVERY AND DEVELOPMENT COMPANY FOCUSED ON NEURODEGENERATIVE DISEASES AND OTHER RELATED DISORDERS. THE PARTNERSHIP WILL COMBINE THE SILVERSTEIN FOUNDATION'S DEEP SCIENTIFIC KNOWLEDGE BASE WITH Q-STATE'S PRECISION MEDICINE PLATFORM, DISEASE-RELEVANT CELLULAR ASSAYS, AND ASO (ANTISENSE-OLIGONUCLEOTIDE) DESIGN CAPABILITIES. CHAMISHI IS LED BY JIM SULLIVAN, FORMER VICE PRESIDENT OF PHARMACEUTICAL DISCOVERY AT ABBVIE. FORM 990, PART VI, SECTION A, LINE 2 DIRECTORS JONATHAN SILVERSTEIN AND NATALIE SILVERSTEIN HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED, USING INFORMATION PROVIDED BY THE FOUNDATION, BY AN INDEPENDENT ACCOUNTING FIRM. THE 990, AS WILL BE FILED WITH THE IRS, IS REVIEWED BY THE BOARD PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION HAS A CONFLICT OF INTEREST POLICY IN PLACE. (A) IF THE FOUNDATION HAS MULTIPLE DIRECTORS, A DIRECTOR WHO IS DIRECTLY OR INDIRECTLY A PARTY TO A TRANSACTION WITH THE FOUNDATION (AN "INTERESTED DIRECTOR") SHALL DISCLOSE THE MATERIAL FACTS OF THE TRANSACTION AND HIS OR HER INTEREST IN OR RELATIONSHIP TO SUCH TRANSACTION TO THE BOARD OF DIRECTORS AND TO ANY COMMITTEE OF THE BOARD CONSIDERING SUCH TRANSACTION PRIOR TO ANY ACTION BY THE BOARD OR SUCH COMMITTEE TO AUTHORIZE, APPROVE OR RATIFY SUCH TRANSACTION. A DIRECTOR IS "INDIRECTLY" A PARTY TO A TRANSACTION IF THE ENTITY WHICH IS A PARTY IS AN ENTITY IN WHICH THE DIRECTOR HAS A MATERIAL FINANCIAL INTEREST OR OF WHICH THE DIRECTOR IS AN OFFICER, DIRECTOR OR GENERAL PARTNER. (B) THE TRANSACTION SHALL BE APPROVED IN GOOD FAITH BY THE BOARD OF DIRECTORS OR A COMMITTEE OF THE BOARD BY THE AFFIRMATIVE VOTE OF: (I) A MAJORITY OF THE DISINTERESTED DIRECTORS; OR (II) A MAJORITY OF ALL THE DIRECTORS ON THE BOARD OR COMMITTEE AFTER DECIDING THAT THE TRANSACTION IS FAIR TO THE FOUNDATION AS OF THE TIME IT IS AUTHORIZED BY THE BOARD OR COMMITTEE. THE PRESENCE OF AN INTERESTED DIRECTOR OR OF A DIRECTOR WHO IS OTHERWISE NOT DISINTERESTED MAY BE COUNTED IN DETERMINING WHETHER A QUORUM OF THE BOARD OF DIRECTORS OR A COMMITTEE OF THE BOARD IS PRESENT. THE BOARD OF DIRECTORS MAY IN ITS DISCRETION ADOPT OTHER PROCEDURES AS THE BOARD DETERMINES IS APPROPRIATE TO ADDRESS CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART X THE BEGINNING OF YEAR INVESTMENTS AND RETAINED EARNINGS WERE RESTATED BY $865,759 TO ADJUST THE UNREALIZED GAINS TO ACTUAL FOR THE PRIOR PERIOD. NO OTHER CHANGES OR RESTATEMENTS WERE MADE.